載入中
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
前收盤價
US$1.87
−US$0.12 · -6.03%
盤中時間採用ET。市場資料可能有所延遲。
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
日內區間
目前US$1.87
52週區間
目前US$1.87
盤中時間採用ET。市場資料可能有所延遲。
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
日內區間
目前US$1.87
52週區間
目前US$1.87
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.24萬 USD | 6331 USD | 15.64萬 USD | 8561 USD | — |
| 銷貨成本 | 4733 USD | 5.94萬 USD | 10.58萬 USD | 9926 USD | — |
| 毛利 | 7690 USD | −5.31萬 USD | 5.06萬 USD | −1365 USD | — |
| 研究與開發 | 373.84萬 USD | 177.98萬 USD | 156.2萬 USD | 39.71萬 USD | 43.37萬 USD |
| 銷售、一般及管理費用 | 266.91萬 USD | 433萬 USD | 459.47萬 USD | 533.43萬 USD | 129.99萬 USD |
| 營業費用 | 640.74萬 USD | 610.98萬 USD | 654.71萬 USD | 573.14萬 USD | 173.37萬 USD |
| 利息支出 | 6.18萬 USD | 5.82萬 USD | 2.69萬 USD | 1.55萬 USD | 1.54萬 USD |
| 折舊和攤銷 | 43.9萬 USD | 34.34萬 USD | 10.31萬 USD | 1 USD | 173.37萬 USD |
| 營業利益 | −639.97萬 USD | −616.29萬 USD | −649.65萬 USD | −573.28萬 USD | −173.37萬 USD |
| 淨利 | −502.38萬 USD | −606.12萬 USD | −673.35萬 USD | −545.75萬 USD | −170.88萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$1.00
下跌空間 46.52%AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
